PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patients
Immunotherapy drugs increase rash risks for cancer patients
This meta-analysis evaluated the risk of developing rashes in cancer patients treated with PD-1 or PD-L1 inhibitors, both alone and in combi…
New data shows that certain immunotherapy drugs used to treat cancer significantly increase the risk of developing skin rashes.
Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
Targeted therapy plus chemotherapy improves response in triple-negative breast cancer
This systematic review and meta-analysis of 523 patients found that adding targeted therapy to chemotherapy for advanced triple-negative bre…
Adding targeted therapy to chemotherapy may improve how tumors respond in patients with advanced triple-negative breast cancer.
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival
This meta-analysis of 3,910 patients with extensive-stage small-cell lung cancer (ES-SCLC) found that first-line immune checkpoint inhibitor…
Combining immune checkpoint inhibitors with chemotherapy shows better survival rates for patients with extensive stage small cell lung cance…
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
New lung cancer treatments show better results but higher costs
This network meta-analysis evaluated the cost-effectiveness of three immunotherapy-based combinations compared to chemotherapy in patients w…
Newer drug combinations offer better survival for certain lung cancer patients, but high costs currently make them difficult to fund widely.
STR genotyping confirms gestational origin of pelvic choriocarcinoma, guiding risk score revision
Genetic testing helps identify the source of rare tumors
This case report describes a 29-year-old woman with pelvic gestational choriocarcinoma whose tumor origin was confirmed via STR genotyping, …
A 29-year-old woman with a rare tumor was treated successfully after genetic testing confirmed the exact origin of her cancer.
Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC
Combination therapy shows mixed results for advanced prostate cancer
This meta-analysis evaluated the addition of PD-1 or PD-L1 inhibitors to chemotherapy for patients with metastatic castration-resistant pros…
Adding immunotherapy to chemotherapy for advanced prostate cancer may not improve survival for all patients and can lead to more severe side…
Chemotherapy plus traditional Chinese medicine improves progression-free survival in advanced non-small cell lung cancer
Traditional Chinese Medicine May Improve Survival in Lung Cancer
This systematic review and meta-analysis of individual patient data analyzed chemotherapy combined with traditional Chinese medicine (TCM) f…
Adding traditional Chinese medicine to chemotherapy may improve survival times for patients with advanced non-small cell lung cancer.
Early postoperative chemotherapy reduces risk of death in patients with colorectal cancer
Early chemotherapy after surgery improves survival for colorectal cancer patients
This meta-analysis of cohort studies involving 72,873 patients found that delayed postoperative chemotherapy significantly increased the ris…
Starting chemotherapy within 8 weeks of surgery significantly improves survival rates for people living with colorectal cancer.
Chemoimmunotherapy improves objective response rate and survival in advanced pulmonary large-cell neuroendocrine carcinoma
Combining Chemotherapy and Immune Therapy Improves Outcomes for Advanced Lung Cancer
This meta-analysis of 3537 patients with advanced pulmonary large-cell neuroendocrine carcinoma (LCNEC) found that chemoimmunotherapy signif…
Adding an immune-boosting drug to standard chemotherapy helps patients with a specific type of advanced lung cancer live longer.
Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
Immunotherapy plus chemo improves survival in triple-negative breast cancer
This umbrella meta-analysis of 39,147 patients found that combining immune checkpoint inhibitors with chemotherapy significantly improves ov…
Adding immunotherapy to chemo helps some patients with advanced triple-negative breast cancer live longer, but side effects are more common.
Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
New Guidelines Redefine Surgery Options for Lung Cancer Patients
This clinical guideline addresses the management of stage III non-small cell lung cancer (NSCLC). It advocates for a multidisciplinary appro…
New guidelines suggest that surgery for certain lung cancers should be based on tumor biology and treatment response rather than just anatom…
Surgical treatment and multimodal therapies characterize management options for rare penile melanoma cases
Treatment Options and Clinical Features for Penile Melanoma
This case series and narrative review describes the clinical features and treatment landscape for patients with penile melanoma. The authors…
New research highlights surgical options and targeted therapies for penile melanoma, a rare form of skin cancer that primarily affects middl…